Lack of hydroxyurea‐associated mutagenesis in pediatric sickle cell disease patients
Sign Up to like & getrecommendations! Published in 2023 at "Environmental and Molecular Mutagenesis"
DOI: 10.1002/em.22536
Abstract: Hydroxyurea is approved for treating children and adults with sickle cell anemia (SCA). Despite its proven efficacy, concerns remain about its mutagenic and carcinogenic potential that hamper its widespread use. Cell culture‐ and animal‐based investigations… read more here.
Keywords: cell; sca patients; mutagenesis; mut ret ... See more keywords